

Chimpanzee adenovirus vaccine generates acute and durable immunity to ebolavirus challenge

Nature Medicine

20, 1126-1129

DOI: [10.1038/nm.3702](https://doi.org/10.1038/nm.3702)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ebola virus disease: where are we now and where do we go?. <i>Postgraduate Medical Journal</i> , 2014, 90, 610-612.	1.8	8
2	Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. <i>Infectious Diseases of Poverty</i> , 2014, 3, 43.	3.7	23
3	Ebola virus: Questions, answers, and more questions. <i>Cleveland Clinic Journal of Medicine</i> , 2014, 81, 729-735.	1.3	4
4	Ebola: a review on the state of the art on prevention and treatment. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2014, 4, 925-927.	1.2	4
5	Ebolavirus in West Africa, and the use of experimental therapies or vaccines. <i>BMC Biology</i> , 2014, 12, 80.	3.8	20
6	Ebola Conquers West Africa – More to Come?. <i>EBioMedicine</i> , 2014, 1, 2-3.	6.1	1
8	Camouflage and Misdirection: The Full-On Assault of Ebola Virus Disease. <i>Cell</i> , 2014, 159, 477-486.	28.9	62
9	Trial of Ebola virus vaccine is due to start next week. <i>BMJ, The</i> , 2014, 349, g5562-g5562.	6.0	3
10	Ebola Virus Potential Drug Targets and Prospects for Small Molecule Drug Discovery. <i>Journal of Pharmaceutical Sciences and Pharmacology</i> , 2014, 1, 313-321.	0.2	1
11	Ebola virus disease: societal challenges and new treatments. <i>Journal of Internal Medicine</i> , 2015, 278, 227-237.	6.0	6
12	One Health, Vaccines and Ebola: The Opportunities for Shared Benefits. <i>Journal of Agricultural and Environmental Ethics</i> , 2015, 28, 1011-1032.	1.7	27
13	Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen. <i>Vaccine</i> , 2015, 33, 7283-7289.	3.8	6
14	Ebola outbreak in Western Africa 2014: what is going on with Ebola virus?. <i>Clinical and Experimental Vaccine Research</i> , 2015, 4, 17.	2.2	44
15	Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material. <i>Viruses</i> , 2015, 7, 6739-6754.	3.3	29
16	A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates. <i>PLoS ONE</i> , 2015, 10, e0143552.	2.5	32
17	Identification of Invariant Peptide Domains within Ebola Virus Glycoprotein GP1, 2., 2015, 04, .		0
18	A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2015, 212, S368-S371.	4.0	38
19	Ebola vaccine R&D: Filling the knowledge gaps. <i>Science Translational Medicine</i> , 2015, 7, 317ps24.	12.4	41

#	ARTICLE	IF	CITATIONS
21	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. <i>Lancet, The</i> , 2015, 385, 1545-1554.	13.7	109
22	Ebola in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 868-871.	2.9	3
23	Ebola virus in West Africa: new conquered territories and new risksâ€™ or how I learned to stop worrying and (not) love Ebola virus. <i>Current Opinion in Virology</i> , 2015, 10, 70-76.	5.4	15
24	Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. <i>Antiviral Research</i> , 2015, 116, 17-19.	4.1	17
25	Measure for measure. <i>Nature</i> , 2015, 518, 439-443.	27.8	12
26	Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 356-359.	9.1	32
27	Ebola and Marburg vaccines for Africa: one step closer. <i>Lancet, The</i> , 2015, 385, 1491-1493.	13.7	4
28	Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine. <i>Molecular Pharmaceutics</i> , 2015, 12, 2697-2711.	4.6	7
29	Ebola. <i>Emergency Medicine Clinics of North America</i> , 2015, 33, e1-e18.	1.2	8
30	Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3050-3055.	7.1	111
31	Human Ebola virus infection results in substantial immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4719-4724.	7.1	274
32	The Evolution of Poxvirus Vaccines. <i>Viruses</i> , 2015, 7, 1726-1803.	3.3	164
33	An updated Ebola vaccine: immunogenic, but will it protect?. <i>Lancet, The</i> , 2015, 385, 2229-2230.	13.7	7
34	Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study. <i>Journal of Infectious Diseases</i> , 2015, 212, S389-S397.	4.0	18
35	Against the clock towards new Ebola virus therapies. <i>Virus Research</i> , 2015, 209, 4-10.	2.2	14
36	An Ebola whole-virus vaccine is protective in nonhuman primates. <i>Science</i> , 2015, 348, 439-442.	12.6	81
37	Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes. <i>ACS Infectious Diseases</i> , 2015, 1, 186-197.	3.8	18
38	Middle East respiratory syndrome: obstacles and prospects for vaccine development. <i>Expert Review of Vaccines</i> , 2015, 14, 949-962.	4.4	27

#	ARTICLE	IF	CITATIONS
39	Ebola virus disease: from epidemiology to prophylaxis. <i>Military Medical Research</i> , 2015, 2, 7.	3.4	22
40	A vaccine against Ebola: Problems and opportunities. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1258-1260.	3.3	6
41	Next-Generation Sequencing Reveals a Controlled Immune Response to Zaire Ebola Virus Challenge in Cynomolgus Macaques Immunized with Vesicular Stomatitis Virus Expressing Zaire Ebola Virus Glycoprotein (VSV ^{ΔG} /EBOVgp). <i>Vaccine Journal</i> , 2015, 22, 354-356.	3.1	21
42	Immunology of protection from Ebola virus infection. <i>Science Translational Medicine</i> , 2015, 7, 286ps11.	12.4	18
43	Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet, The</i> , 2015, 385, 2272-2279.	13.7	149
44	A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 527-530.	4.4	3
45	Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. <i>Nature</i> , 2015, 520, 688-691.	27.8	84
46	Chimpanzee Adenovirus Vector Ebola Vaccine – Preliminary Report. <i>New England Journal of Medicine</i> , 2015, 373, 775-776.	27.0	147
47	Providing incentives to share data early in health emergencies: the role of journal editors. <i>Lancet, The</i> , 2015, 386, 1797-1798.	13.7	40
48	Clinical development of Ebola vaccines. <i>Therapeutic Advances in Vaccines</i> , 2015, 3, 125-138.	2.7	65
49	Immunology and evolution of the adenovirus prime, MVA boost Ebola virus vaccine. <i>Current Opinion in Immunology</i> , 2015, 35, 131-136.	5.5	33
50	Adenovirus-vectored Ebola vaccines. <i>Expert Review of Vaccines</i> , 2015, 14, 1347-1357.	4.4	17
51	Ebola hemorrhagic fever: Properties of the pathogen and development of vaccines and chemotherapeutic agents. <i>Molecular Biology</i> , 2015, 49, 480-493.	1.3	7
52	Ebola virus vaccine: benefit and risks of adenovirus-based vectors. <i>Expert Review of Vaccines</i> , 2015, 14, 1471-1478.	4.4	13
53	A race for an Ebola vaccine: promises and obstacles. <i>Trends in Microbiology</i> , 2015, 23, 65-66.	7.7	19
54	A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. <i>Molecular Pharmaceutics</i> , 2015, 12, 2712-2731.	4.6	46
55	Potential and Emerging Treatment Options for Ebola Virus Disease. <i>Annals of Pharmacotherapy</i> , 2015, 49, 196-206.	1.9	94
56	A brief history of primate research: Global health improvements and ethical challenges. <i>Archives of Medical and Biomedical Research</i> , 2016, 2, 151.	0.2	3

#	ARTICLE	IF	CITATIONS
57	Xenogenic Adenoviral Vectors. , 2016, , 495-528.		5
58	Ebola virus “ from neglected threat to global emergency state. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2016, 62, 458-467.	0.7	1
59	Advancements in the Therapy of Ebola Virus Disease. Pediatric Infectious Diseases Open Access, 2016, 01, .	0.0	0
60	Ebola Virus. , 2016, , 355-362.		0
61	Methods to Mitigate Immune Responses to Adenoviral Vectors. , 2016, , 391-422.		2
62	How are Vaccines Assessed in Clinical Trials?. , 2016, , 97-119.		0
63	Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0004464.	3.0	20
64	Vaccines for Emerging Viral Diseases. , 2016, , 543-560.		1
65	Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months. Nature Communications, 2016, 7, 13520.	12.8	86
66	Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays. Scientific Reports, 2016, 6, 23803.	3.3	20
67	Vaccines against “the other”™ Ebolavirus species. Expert Review of Vaccines, 2016, 15, 1093-1100.	4.4	6
68	Microbiomes, metagenomics, and primate conservation: New strategies, tools, and applications. Biological Conservation, 2016, 199, 56-66.	4.1	73
69	Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus. Methods in Molecular Biology, 2016, 1403, 245-257.	0.9	6
70	Ebola virus vaccines “ reality or fiction?. Expert Review of Vaccines, 2016, 15, 1421-1430.	4.4	29
71	Safety and Immunogenicity of Novel Adenovirus Type 26“ and Modified Vaccinia Ankara“Vectored Ebola Vaccines. JAMA - Journal of the American Medical Association, 2016, 315, 1610.	7.4	266
72	Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Review of Vaccines, 2016, 15, 1101-1112.	4.4	50
73	Ebola vaccines “ Where are we?. Human Vaccines and Immunotherapeutics, 2016, 12, 2700-2703.	3.3	3
74	Maladie Ã virus EbolaÂ: actualitÃ©s thÃ©rapeutiques. Journal Des Anti-infectieux, 2016, 18, 117-125.	0.1	2

#	ARTICLE	IF	CITATIONS
75	Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a. <i>Clinical Immunology</i> , 2016, 173, 87-95.	3.2	34
76	Ebola virus disease and critical illness. <i>Critical Care</i> , 2016, 20, 217.	5.8	97
78	An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2016, 214, S326-S332.	4.0	28
79	Molecular mechanisms of Ebola pathogenesis. <i>Journal of Leukocyte Biology</i> , 2016, 100, 889-904.	3.3	31
80	BoHV-4-based vector delivering Ebola virus surface glycoprotein. <i>Journal of Translational Medicine</i> , 2016, 14, 325.	4.4	8
81	Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells. <i>Journal of Immunology</i> , 2016, 197, 1809-1822.	0.8	41
82	Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 21674.	3.3	54
83	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. <i>Nature Microbiology</i> , 2016, 1, 16128.	13.3	92
84	Ebola virus vaccines: Where do we stand?. <i>Clinical Immunology</i> , 2016, 173, 44-49.	3.2	32
86	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	1
87	The 2014-2015 Ebola outbreak in West Africa: Hands On. <i>Antimicrobial Resistance and Infection Control</i> , 2016, 5, .	4.1	55
88	Integrated sequence and immunology filovirus database at Los Alamos. <i>Database: the Journal of Biological Databases and Curation</i> , 2016, 2016, baw047.	3.0	3
89	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	27.0	295
90	Duration of immune responses after Ebola virus vaccination. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 2-3.	9.1	4
91	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. <i>Clinical Trials</i> , 2016, 13, 49-56.	1.6	63
92	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. <i>Vaccine</i> , 2016, 34, 49-55.	3.8	13
93	Prediction and conservancy analysis of promiscuous T-cell binding epitopes of Ebola virus L protein: An in silico approach. <i>Asian Pacific Journal of Tropical Disease</i> , 2016, 6, 169-173.	0.5	9
94	Adenoviral Vectors Vaccine. , 2016, , 571-590.		1

#	ARTICLE	IF	CITATIONS
95	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 31-42.	9.1	187
96	Vaccine Targeting of Subdominant CD8+ T Cell Epitopes Increases the Breadth of the T Cell Response upon Viral Challenge, but May Impair Immediate Virus Control. <i>Journal of Immunology</i> , 2016, 196, 2666-2676.	0.8	4
97	Ebola virus disease: emergence, outbreak and future directions. <i>British Medical Bulletin</i> , 2016, 117, 95-106.	6.9	21
98	Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. <i>Vaccine</i> , 2016, 34, 1927-1935.	3.8	106
99	Safety and immunogenicity of a chimpanzee adenovirus-vectorized Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 311-320.	9.1	133
100	Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. <i>Virus Research</i> , 2016, 213, 224-229.	2.2	23
101	Development and Characterization of a Guinea Pig-Adapted Sudan Virus. <i>Journal of Virology</i> , 2016, 90, 392-399.	3.4	42
102	Recent advances in the development of vaccines for Ebola virus disease. <i>Virus Research</i> , 2016, 211, 174-185.	2.2	38
103	Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs. <i>Molecular Therapy</i> , 2016, 24, 6-16.	8.2	85
104	Towards detection and diagnosis of Ebola virus disease at point-of-care. <i>Biosensors and Bioelectronics</i> , 2016, 75, 254-272.	10.1	127
106	Chimpanzee Adenovirus Vector Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 928-938.	27.0	243
107	One Step Closer to an Ebola Virus Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 984-985.	27.0	12
108	Immunobiology of Ebola and Lassa virus infections. <i>Nature Reviews Immunology</i> , 2017, 17, 195-207.	22.7	95
109	Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectorized Ebola vaccine: An open phase I/II trial in healthy adults in Russia. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 613-620.	3.3	92
110	Modified Vaccinia Virus Ankara. <i>Advances in Virus Research</i> , 2017, 97, 187-243.	2.1	233
111	Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys. <i>Journal of Virology</i> , 2017, 91, .	3.4	13
112	Multivalent Glycosylated Nanostructures To Inhibit Ebola Virus Infection. <i>Journal of the American Chemical Society</i> , 2017, 139, 6018-6025.	13.7	104
113	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160295.	4.0	33

#	ARTICLE	IF	CITATIONS
114	Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2364-2368.	2.2	18
115	Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection. <i>Scientific Reports</i> , 2017, 7, 919.	3.3	31
116	Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. <i>Genes and Diseases</i> , 2017, 4, 43-63.	3.4	451
117	Ebola and Marburg virus vaccines. <i>Virus Genes</i> , 2017, 53, 501-515.	1.6	70
119	Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models. <i>Virus Genes</i> , 2017, 53, 684-691.	1.6	25
120	Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology. <i>Vaccine</i> , 2017, 35, 4461-4464.	3.8	28
121	Closer than ever to an Ebola virus vaccine. <i>Expert Review of Vaccines</i> , 2017, 16, 401-402.	4.4	5
122	Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 621-628.	13.7	168
123	Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. <i>The Lancet Global Health</i> , 2017, 5, e324-e334.	6.3	85
124	Ebola in great apes – current knowledge, possibilities for vaccination, and implications for conservation and human health. <i>Mammal Review</i> , 2017, 47, 98-111.	4.8	40
125	Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane. <i>Expert Review of Vaccines</i> , 2017, 16, 1241-1252.	4.4	43
126	A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. <i>Antiviral Research</i> , 2017, 145, 54-59.	4.1	10
127	Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants. <i>Current Opinion in Immunology</i> , 2017, 47, 1-7.	5.5	34
128	The latest advancements in Zika virus vaccine development. <i>Expert Review of Vaccines</i> , 2017, 16, 951-954.	4.4	12
129	Novel Concepts for HIV Vaccine Vector Design. <i>MSphere</i> , 2017, 2, .	2.9	11
130	Production and Purification of Filovirus Glycoproteins in Insect and Mammalian Cell Lines. <i>Scientific Reports</i> , 2017, 7, 15091.	3.3	11
131	Ebola vaccines in clinical trial: The promising candidates. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 153-168.	3.3	48
132	Multivalent and Multipathogen Viral Vector Vaccines. <i>Vaccine Journal</i> , 2017, 24, .	3.1	80

#	ARTICLE	IF	CITATIONS
133	Ebola virus disease: An update on current prevention and management strategies. <i>Journal of Clinical Virology</i> , 2017, 86, 5-13.	3.1	25
134	Marburg- and Ebolaviruses. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	1.1	4
135	A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus. <i>Frontiers in Immunology</i> , 2017, 8, 252.	4.8	23
136	T Helper 17 Promotes Induction of Antigen-Specific Gut-Mucosal Cytotoxic T Lymphocytes following Adenovirus Vector Vaccination. <i>Frontiers in Immunology</i> , 2017, 8, 1456.	4.8	6
137	Fighting Ebola: A Window for Vaccine Re-evaluation?. <i>PLoS Pathogens</i> , 2017, 13, e1006037.	4.7	13
138	New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model. <i>Malaria Journal</i> , 2017, 16, 263.	2.3	13
139	Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins. <i>Journal of Virology</i> , 2018, 92, .	3.4	36
141	Post-exposure treatments for Ebola and Marburg virus infections. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 413-434.	46.4	104
142	A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. <i>Scientific Reports</i> , 2018, 8, 864.	3.3	43
143	Development of novel vaccine vectors: Chimpanzee adenoviral vectors. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1679-1685.	3.3	56
144	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. <i>Nature Biotechnology</i> , 2018, 36, 152-155.	17.5	109
145	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. <i>Microbiology Spectrum</i> , 2018, 6, .	3.0	6
146	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028902.	5.5	31
147	Structure based virtual screening of the Ebola virus trimeric glycoprotein using consensus scoring. <i>Computational Biology and Chemistry</i> , 2018, 72, 170-180.	2.3	45
148	Disaster Preparedness: Biological Threats and Treatment Options. <i>Pharmacotherapy</i> , 2018, 38, 217-234.	2.6	30
149	Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. <i>Nature Immunology</i> , 2018, 19, 20-28.	14.5	110
150	Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e183-e192.	9.1	112
151	Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge. <i>Journal of Virology</i> , 2018, 92, .	3.4	34

#	ARTICLE	IF	CITATIONS
152	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 159-173.	3.1	35
153	Vaccines against Ebola virus. <i>Vaccine</i> , 2018, 36, 5454-5459.	3.8	43
154	Bioinformatics Approach to Screening and Developing Drug against Ebola. , 0, , .		0
155	A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006530.	3.0	5
156	Antibody-mediated protection against Ebola virus. <i>Nature Immunology</i> , 2018, 19, 1169-1178.	14.5	127
157	Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction. <i>Journal of Infectious Diseases</i> , 2018, 218, S537-S544.	4.0	3
158	Will a Single-Cycle Adenovirus Vaccine Be Effective Against Ebola Virus?. <i>Journal of Infectious Diseases</i> , 2018, 218, 1858-1860.	4.0	0
159	Ebola: Lessons on Vaccine Development. <i>Annual Review of Microbiology</i> , 2018, 72, 423-446.	7.3	51
160	Ebola Immunity: Gaining a Winning Position in Lightning Chess. <i>Journal of Immunology</i> , 2018, 201, 833-842.	0.8	19
161	Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge. <i>Scientific Reports</i> , 2018, 8, 11193.	3.3	26
162	Qualitative Profiling of the Humoral Immune Response Elicited by rVSV- $\hat{\Gamma}$ G-EBOV-GP Using a Systems Serology Assay, Domain Programmable Arrays. <i>Cell Reports</i> , 2018, 24, 1050-1059.e5.	6.4	11
163	Correlates of vaccine-induced protective immunity against Ebola virus disease. <i>Seminars in Immunology</i> , 2018, 39, 65-72.	5.6	44
164	Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. <i>Vaccines</i> , 2018, 6, 50.	4.4	54
165	Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 1025.	4.8	12
166	Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures. <i>Journal of Infectious Diseases</i> , 2018, 218, S528-S536.	4.0	17
167	A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. <i>Journal of Infectious Diseases</i> , 2018, 218, 1883-1889.	4.0	14
168	Ebola virus “ prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine. <i>Expert Review of Vaccines</i> , 2018, 17, 769-771.	4.4	1
169	Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. <i>International Journal of Infectious Diseases</i> , 2018, 74, 83-96.	3.3	21

#	ARTICLE	IF	CITATIONS
170	New Vaccine Technologies to Combat Outbreak Situations. <i>Frontiers in Immunology</i> , 2018, 9, 1963.	4.8	437
171	DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost. <i>Scientific Reports</i> , 2018, 8, 12459.	3.3	21
172	An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	6.5	16
173	Construction and characterization of bacterial artificial chromosomes harboring the full-length genome of a highly attenuated vaccinia virus LC16m8. <i>PLoS ONE</i> , 2018, 13, e0192725.	2.5	6
174	Development of Gene-Based Vectors for Immunization. , 2018, , 1305-1319.e8.		3
175	Ebola Vaccines. , 2018, , 276-287.e5.		0
176	Inactivated Influenza Vaccines. , 2018, , 456-488.e21.		14
177	Poxviral promoters for improving the immunogenicity of MVA delivered vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 203-209.	3.3	22
178	Chimpanzee adenoviral vector prime-boost regimen elicits potent immune responses against Ebola virus in mice and rhesus macaques. <i>Emerging Microbes and Infections</i> , 2019, 8, 1086-1097.	6.5	13
179	Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2359-2377.	3.3	31
180	The Antiviral and Antitumor Effects of Defective Interfering Particles/Genomes and Their Mechanisms. <i>Frontiers in Microbiology</i> , 2019, 10, 1852.	3.5	43
181	A Gorilla Adenovirus-Based Vaccine against Zika Virus Induces Durable Immunity and Confers Protection in Pregnancy. <i>Cell Reports</i> , 2019, 28, 2634-2646.e4.	6.4	19
182	Ebola Virus: Pathogenesis and Countermeasure Development. <i>Annual Review of Virology</i> , 2019, 6, 435-458.	6.7	50
183	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019, 219, 1187-1197.	4.0	59
184	Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. <i>PLoS ONE</i> , 2019, 14, e0215457.	2.5	35
185	Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epitope vaccine. <i>PLoS Pathogens</i> , 2019, 15, e1007564.	4.7	20
187	Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. <i>Cell Reports</i> , 2019, 27, 172-186.e7.	6.4	69
188	Molecular modelling studies on adamantane-based Ebola virus GP-1 inhibitors using docking, pharmacophore and 3D-QSAR. <i>SAR and QSAR in Environmental Research</i> , 2019, 30, 161-180.	2.2	26

#	ARTICLE	IF	CITATIONS
189	Transmission, Human Population, and Pathogenicity: the Ebola Case in Point. , 2019, , 263-278.		0
190	Ebola vaccine trials: progress in vaccine safety and immunogenicity. <i>Expert Review of Vaccines</i> , 2019, 18, 1229-1242.	4.4	61
191	A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice. <i>Viruses</i> , 2019, 11, 1149.	3.3	11
192	On the stability of sequences inserted into viral genomes. <i>Virus Evolution</i> , 2019, 5, vez045.	4.9	41
193	Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?. <i>Trends in Microbiology</i> , 2019, 27, 8-16.	7.7	32
194	Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 414-425.	3.3	17
195	Antigen-specific CD8 T cells in cell cycle circulate in the blood after vaccination. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12735.	2.7	18
196	Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebola virus Vaccine. <i>Journal of Virology</i> , 2019, 93, .	3.4	13
197	Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs. <i>Vaccine</i> , 2019, 37, 7178-7182.	3.8	7
198	Ebola virus disease: An emerging and re-emerging viral threat. <i>Journal of Autoimmunity</i> , 2020, 106, 102375.	6.5	79
199	Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease. <i>Pathogens</i> , 2020, 9, 850.	2.8	16
200	Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2. <i>Npj Vaccines</i> , 2020, 5, 98.	6.0	26
201	New viral vectors for infectious diseases and cancer. <i>Seminars in Immunology</i> , 2020, 50, 101430.	5.6	55
202	Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. <i>Immunologic Research</i> , 2020, 68, 325-339.	2.9	39
203	How the COVID-19 pandemic highlights the necessity of animal research. <i>Current Biology</i> , 2020, 30, R1014-R1018.	3.9	26
204	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1817.	4.8	189
205	Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. <i>Npj Vaccines</i> , 2020, 5, 94.	6.0	15
206	Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection. <i>Npj Vaccines</i> , 2020, 5, 78.	6.0	10

#	ARTICLE	IF	CITATIONS
207	Marburg virus disease: A summary for clinicians. <i>International Journal of Infectious Diseases</i> , 2020, 99, 233-242.	3.3	67
208	The Effect of Residual Triton X-100 on Structural Stability and Infection Activity of Adenovirus Particles. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 19, 35-46.	4.1	8
209	Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques. <i>Npj Vaccines</i> , 2020, 5, 39.	6.0	13
210	The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. <i>Immunology</i> , 2020, 160, 223-232.	4.4	86
211	Chimpanzee adenovirus type 3 vectored Ebola vaccine: expanding the field. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 636-637.	9.1	1
212	The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms. <i>Expert Review of Vaccines</i> , 2020, 19, 267-277.	4.4	17
213	Nonclinical safety assessment of repeated administration and biodistribution of ChAd3â€EBOâ€Z Ebola candidate vaccine. <i>Journal of Applied Toxicology</i> , 2020, 40, 748-762.	2.8	7
214	Structural Basis for a Convergent Immune Response against Ebola Virus. <i>Cell Host and Microbe</i> , 2020, 27, 418-427.e4.	11.0	25
215	A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	17
216	Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 707-718.	9.1	45
217	Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2855-2860.	3.3	7
218	What policy makers need to know about COVID-19 protective immunity. <i>Lancet</i> , The, 2020, 395, 1527-1529.	13.7	188
219	Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 507-516.	9.1	26
220	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 493-506.	9.1	115
221	Multivalent Glycosylated Carbon Nanostructures: Efficient Inhibitors of Emergent Viruses Infection. <i>RSC Nanoscience and Nanotechnology</i> , 2021, , 56-97.	0.2	2
222	Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013â€16 West Africa epidemic. <i>Nature Communications</i> , 2021, 12, 1153.	12.8	10
223	SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1626.	2.6	17
224	Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection. <i>Frontiers in Immunology</i> , 2020, 11, 599568.	4.8	16

#	ARTICLE	IF	CITATIONS
225	Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates. <i>Frontiers in Immunology</i> , 2021, 12, 627688.	4.8	3
226	Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack. <i>Cell Reports Medicine</i> , 2021, 2, 100209.	6.5	16
227	A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. <i>European Journal of Immunology</i> , 2021, 51, 1774-1784.	2.9	30
228	Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties. <i>Viruses</i> , 2021, 13, 1221.	3.3	9
229	The contribution of veterinary public health to the management of the COVID-19 pandemic from a One Health perspective. <i>One Health</i> , 2021, 12, 100230.	3.4	21
230	Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases. <i>Viruses</i> , 2021, 13, 1493.	3.3	9
231	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2021, 9, 848.	4.4	64
232	Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice. <i>Archives of Virology</i> , 2021, 166, 3333-3341.	2.1	5
233	Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers. <i>Vaccine</i> , 2021, 39, 6174-6181.	3.8	9
235	Accelerating Vaccine Development During the 2013-2016 West African Ebola Virus Disease Outbreak. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 229-261.	1.1	14
236	The Threat from Viruses. , 2018, , 45-76.		7
237	Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. <i>Journal of Clinical Investigation</i> , 2015, 125, 1129-1146.	8.2	97
238	Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: A cross-sectional study. <i>PLoS Medicine</i> , 2017, 14, e1002300.	8.4	25
239	A Rapid Screening Assay Identifies Monotherapy with Interferon- γ and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004364.	3.0	48
240	Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004802.	3.0	8
241	Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform. <i>PLoS ONE</i> , 2017, 12, e0174728.	2.5	14
242	A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. <i>PLoS ONE</i> , 2018, 13, e0192312.	2.5	64
243	Method feasibility for cross-species testing, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples. <i>PLoS ONE</i> , 2020, 15, e0241016.	2.5	7

#	ARTICLE	IF	CITATIONS
244	One Health: Addressing Global Challenges at the Nexus of Human, Animal, and Environmental Health. PLoS Pathogens, 2016, 12, e1005731.	4.7	62
245	Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape. Discoveries, 2020, 8, e121.	2.3	15
246	Implementing an Ebola Vaccine Study in Sierra Leone. MMWR Supplements, 2016, 65, 98-106.	35.0	60
247	Virus-Vectored Ebola Vaccines. Acta Naturae, 2017, 9, 4-11.	1.7	24
248	Viral Vector Vaccines against Bluetongue Virus. Microorganisms, 2021, 9, 42.	3.6	14
249	Ebola virus disease: Essential clinical knowledge. Avicenna Journal of Medicine, 2017, 07, 96-102.	0.8	12
250	Initiating a watch list for Ebola virus antibody escape mutations. PeerJ, 2016, 4, e1674.	2.0	36
251	Ebola Vaccine: How Far are we?. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, DE01-DE04.	0.8	4
252	Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform. Frontiers in Oncology, 2021, 11, 732166.	2.8	6
253	Combined Use of Information Entropy and Bepired Scores for Screening Ebola Virus Glycoprotein (GP) Sequences. , 0, , .		1
254	Values and Hopes of Ebola Vaccines Mass Immunization Programs and Treatments Adoption and Implementation Benefits in Africa. International Journal of Vaccines & Vaccination, 2015, 1, .	0.3	3
255	Immunization Against Viral Diseases. , 0, , 351-370.		2
256	Filoviruses. , 0, , 981-1007.		1
257	Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities. , 0, , 53-71.		1
258	Arboviroses et fièvres hémorragiques : actualités épidémiologique et vaccinale. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 1617-1630.	0.0	0
259	Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus disease. EFSA Journal, 2017, 15, e04890.	1.8	1
260	The Peak in Africa (September 2014). , 2018, , 81-123.		0
261	Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
263	Ebola Virus Disease: Progress So Far in the Management of the Disease. , 0, , .		0
264	Swords to Ploughshares and Back: The Continuing Threat of Immunomodulatory Research and Development. , 2019, , 195-223.		0
265	Characterization of Recombinant Chimpanzee Adenovirus C68 Low and High-Density Particles: Impact on Determination of Viral Particle Titer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 753480.	4.1	5
266	Updates on Treatment of Ebola Virus Disease. <i>The Malaysian Journal of Medical Sciences</i> , 2015, 22, 54-57.	0.5	0
267	Virus-Vectored Ebola Vaccines. <i>Acta Naturae</i> , 2017, 9, 4-11.	1.7	3
268	Adenovirus vector-based vaccine for infectious diseases. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100432.	2.2	55
269	The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 . Bluetongue Virus Challenge. <i>Journal of Virology</i> , 2022, 96, JVI0161421.	3.4	5
270	Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies. <i>RSC Drug Discovery Series</i> , 2021, , 91-120.	0.3	0
271	Adenovirus-based vaccinesâ€™ a platform for pandemic preparedness against emerging viral pathogens. <i>Molecular Therapy</i> , 2022, 30, 1822-1849.	8.2	24
272	Filoviruses: modern solutions to life-threatening infections. , 2022, , 369-394.		0
273	Vaccine Licensure in the Absence of Human Efficacy Data. <i>Vaccines</i> , 2022, 10, 368.	4.4	8
274	Identification of Recombinant Chimpanzee Adenovirus C68 Degradation Products Detected by AEX-HPLC. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 753481.	4.1	0
281	Neutralizing Antibody Titer Test of Ebola Recombinant Protein Vaccine and Gene Vector Vaccine pVR-GP-FC. <i>Biomedical and Environmental Sciences</i> , 2018, 31, 721-728.	0.2	1
282	Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.	5.5	28
284	Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein. <i>Antibody Therapeutics</i> , 2022, 5, 177-191.	1.9	6
285	Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccinationâ€™Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay. <i>Vaccines</i> , 2022, 10, 1211.	4.4	5
286	Conformation-Stabilized Amorphous Nanocoating for Rational Design of Long-Term Thermostable Viral Vaccines. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 39873-39884.	8.0	4
287	Bridging Animal and Human Data in Pursuit of Vaccine Licensure. <i>Vaccines</i> , 2022, 10, 1384.	4.4	3

#	ARTICLE	IF	CITATIONS
288	Single-dose of a replication-competent adenovirus-vectored vaccine provides sterilizing protection against Rift Valley fever virus challenge. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
289	Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs. <i>Vaccines</i> , 2022, 10, 1935.	4.4	2
290	Durable CD8 T Cell Memory against SARS-CoV-2 by Prime/Boost and Multi-Dose Vaccination: Considerations on Inter-Dose Time Intervals. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14367.	4.1	4
291	A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	10
292	Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. <i>Lancet, The</i> , 2023, 401, 294-302.	13.7	17
293	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	23
295	The potential epidemic threat of Ebola virus and the development of a preventive vaccine. <i>Journal of Biosafety and Biosecurity</i> , 2023, 5, 67-78.	2.8	0
296	Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. <i>Cell Reports</i> , 2023, 42, 112599.	6.4	1
297	A new vaccination regimen using adenovirus-vectored vaccine confers effective protection against African swine fever virus in swine. <i>Emerging Microbes and Infections</i> , 2023, 12, .	6.5	5
298	Advancements in Marburg (MARV) Virus Vaccine Research With Its Recent Reemergence in Equatorial Guinea and Tanzania: A Scoping Review. <i>Cureus</i> , 2023, , .	0.5	2
299	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
300	Ebola Vaccines. , 2023, , 311-329.e6.		0
301	Inactivated and Recombinant Influenza Vaccines. , 2023, , 514-551.e31.		0
302	Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial. <i>Lancet Infectious Diseases, The</i> , 2023, 23, 1408-1417.	9.1	6
303	Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
305	Ebola virus. <i>Uirusu</i> , 2019, 69, 119-128.	0.1	0
306	Comparison of the Efficacy of Different Schemes for Using Recombinant Vector Vaccines against Ebola Fever, Based on Vaccinia Virus, MVA Strain. <i>Problemy Osobo Opasnykh Infektsii</i> , 2024, , 24-31.	0.6	0
307	Ebola and Marburg viruses. , 2024, , 2281-2308.		0

#	ARTICLE	IF	CITATIONS
308	An adenovirus-vectored vaccine based on the N protein of feline coronavirus elicit robust protective immune responses. <i>Antiviral Research</i> , 2024, 223, 105825.	4.1	0
309	Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution. <i>Engineering Microbiology</i> , 2024, 4, 100140.	4.7	0
311	Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications. <i>Viruses</i> , 2024, 16, 377.	3.3	0